NEW YORK, Nov. 13 – Third Wave Technologies has licensed over 3,300 genetic markers from Japan’s Institute of Physical and Chemical Research, the organizations announced Tuesday.

The agreement gives Third Wave Technologies, based in Madison, Wis., the worldwide license, excluding Japan, to research and clinical diagnostic applications to patents for genetic markers within approximately 200 genes related to drug metabolism regulation, according to the company.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.